Introduction
For many medical conditions there are several treatment options available to the patient.
For example, carpal tunnel syndrome (CTS) can be treated surgically or with conservative therapy that includes physical therapy and anti-inflammatory medications. Conservative therapy is less invasive and less expensive than surgery and is preferable from those points of view. However, it is probably not as effective as surgery, at least in some patients. A simple randomized trial to compare surgery and conservative therapy is currently underway at the University of Washington. All patients in the trial receive magnetic resonance neurographic imaging (MRNI) at baseline. Although the MRNI does not influence treatment within the clinical trial, it is thought that the MRNI score may be an indicator of which patients are likely to benefit more from surgery and could be used in the future to select patients for surgery versus conservative therapy. This paper addresses statistical techniques to evaluate the capacity of a measure, denoted by Y , to assist in treatment selection. The issue is important not only for our study but more generally and particularly in this era of rapidly expanding biotechnology. One of the promises of new biotechnologies, including gene expression arrays and imaging modalities, is to provide information for the purpose of selecting optimal treatment of disease (ElmerDewitt et al., 2001) . It is clearly important that appropriate statistical techniques are in place to critically evaluate the technologies before they are adopted for widespread use.
In Section 2 we present a graphical display, the selection impact (SI) curve that directly describes the performance of the measure Y for treatment selection. We contrast this with existing approaches. Next we propose methods for estimating the SI curve with data from a randomized trial. A nonparametric estimator described in Section 3 and a parametric estimator described in Section 4 are contrasted in the following two sections, using asymptotic theory and small sample simulation studies. Data, simulated to reflect anticipated results from the CTS randomized trial, are analyzed in Section 7. We close in Section 8 with suggestions for future research.
The Selection Impact Curve 1. Definition and Purpose
First we define some notation. Let T be a binary variable that denotes treatment. For simplicity we suppose that there are two treatment options available in the population, A and B. Let T = 1 for A and T = 0 for B. Using the notion of potential responses (Rubin, 1974 (Rubin, , 1978 Holland, 1986) , for t = 0, 1, we define D t as the response if a subject receives treatment T = t. It is impossible to observe D 0 and D 1 on the same subject;
instead, D = T D 1 + (1 − T )D 0 is observed. In this paper, we consider the case that D t is dichotomous, D t = 1 for success and D t = 0 for failure. Extensions to nondichotomous outcomes are discussed in Section 8. We assume that an individual's response to treatment does not depend on the assignment mechanism or the assignments or responses of other individuals to treatments, i.e., the SUTVA assumption of Rubin (1986) We focus on simple thresholding criteria because, at least in our experience, criteria of this 
That is, θ is the proportion of subjects in the population who respond if the treatment policy in effect is to assign a subject to treatment A if his marker value exceeds c but to assign him to treatment B otherwise. Observe that when c = −∞, the policy is that all patients receive treatment A and none receive B, while for c = ∞ all patients receive treatment B.
As c increases from −∞ to ∞, the proportion of subjects assigned to treatment B increases from 0 to 1. Figure 1 displays a schematic illustration of the population response rate as c varies from −∞ to +∞. In the illustration, the overall response rate is higher when all patients are on treatment A than when all are on treatment B. The curve indicates however that a policy that assigns 40% of patients to treatment B and 60% to treatment A on the basis of Y , can perform almost as well as one that assigns 100% of patients to treatment A.
If treatment B is substantially less expensive or invasive than A, as is the case in the CTS study, then this represents a better treatment policy.
The SI curve shows the impact on population response rates of treatment selection criteria based on Y exceeding a threshold. We show the curve, θ(v), as a function of
rather than as a function of c itself. There are two reasons for this. First, in evaluating a treatment policy of this sort, it will be important to know the fractions of subjects potentially assigned to treatment A versus B by the policy, 1 − v and v, respectively. Indeed it is the 3 trade-off between the overall population response rate achieved and v that is of key interest.
If satisfactory operating points are found, (v, θ(v) ), then one can ascertain the corresponding thresholds to implement the policy. Second, the display on this scale allows one to compare policies based on different markers. SI curves for two hypothetical markers are shown in the right panel of Figure 1 . The measurement units of the two markers, Y 1 and Y 2 , say, are irrelevant for the purposes of comparing selection policies based on them. Rather, policies that assign equal fractions of the patient populations to treatment B more naturally compare the markers. We see in Figure 1 that when the thresholds for the two markers, c 1 and c 2 ,
In summary, the SI curve provides a natural common scale for comparing response rates achieved with treatment selection policies based on different markers.
Receiver operating characteristic curves that are used to evaluate and compare operating characteristic of diagnostic tests are motivated by similar notions (Pepe 2003) . Test positive criteria are defined by thresholding the test result and consequent sensitivity and specificity values are plotted. This provides a practically relevant scale for evaluating tests and an appropriate common scale for comparing tests.
In summary, we propose the SI curve as a simple graphical device that shows the population response rates potentially achieved with treatment assignment policies based on the marker exceeding a threshold or not. It can be used to determine if, by using the marker, there is potential to treat fewer patients with an invasive expensive treatment while maintaining the overall proportion of subjects responding at or above that achieved by sending all patients to that treatment. It can suggest an optimal threshold value. Finally, it provides a natural common scale on which to compare different treatment selection markers.
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A traditional statistical approach to evaluating differential treatment benefit is to use binary regression models for the response variable D with treatment, T , and the measure, Y , as covariates. See Byar (1985) and references therein. In this traditional framework an interaction between Y and T is interpreted to mean that Y informs about the relative performance of the treatments. Suppose for example we fit the model
and consider the coefficient α 4 for interaction. The quantity exp(α 4 ) is the increase in the odds ratio associated with treatment A versus B per unit increase in Y . This seems a few steps removed from quantifying the potential impact on the population of using Y to select treatment. The SI curve does this more directly. Moreover, one can find settings where there is no statistical interaction between Y and T in the regression model, but the marker is informative (see setting 7 of Figure 2 ). This is because the definition of interaction in a regression model depends on the metric on which the linear predictor is defined. Thus data that yield an interaction when a logistic link function is used may yield no interaction when another link function is used. The SI curve does not depend on the somewhat arbitrary definition of interaction that the regression framework does. It simply shows the population response rates according to treatment selection criteria based on Y exceeding a threshold.
Other Features of the SI Curve
We write y v for the v th quantile of Y in the population so that v = P[Y < y v ]. The SI curve also shows the following entities that are important measures of the value of the 5 treatment policy that uses the threshold y v for deciding on patient treatment: for patients below the v th quantile when they are given treatment B versus A. Ideally, the threshold y v is chosen so that both groups of patients benefit by the policy, i.e., d
Moreover, we can write
It follows that
Similar arguments show that
Thus the distances between the SI curve and the upper and lower horizontal lines in Figure 1 An uninformative marker is one that does not identify subsets of patients that benefit more than others do by their assigned treatment. That is, an uninformative marker is defined as one for which
for all v. Thus, for the uninformative marker d
it follows that θ(v) is a straight line connecting θ(1) to θ(0) for the uninformative marker.
This serves as a baseline SI curve against which others can be compared. Observe that the uninformative marker may be associated with treatment response. It simply does not inform about which patients are likely to benefit more than the average from treatment A versus B or vice versa.
Our SI curve displays d + (v) and d − (v), the differences in response rates with treatments A and B for the population that meets the criterion Y > y v and that which does not. In setting forth a treatment policy for a population, consideration of the population as a whole that meets the criterion (or not) is most relevant. Nevertheless, an individual patient with marker value Y = y, will be more interested in his/her own probabilities of response with 7 the two treatments. We write
With knowledge of the risks and costs associated with treatments A versus B and the difference in response probabilities d(v), an individual patient and caregiver may decide on which treatment to select. However, in our experience such individual decision making is a luxury not always afforded by the healthcare system and, as mentioned earlier, simple dichotomous criteria such as Y exceeding a percentile threshold are often used to make medical decisions. Policy makers will be interested in the impact of such criteria on the overall response probabilities, i.e., the quantities shown in the SI curve,
In addition, we will see that d(v) is much more difficult to estimate from data than are the cumulative versions We also discuss parametric estimation of θ(v) in Section 4 using parametric modeling of 
Nonparametric Estimation
We now turn to estimation of θ(v). Data from a randomized trial conducted in the population can be used for estimation if some intuitively reasonable conditions are met. These include:
(i) subjects enrolled in the trial are a simple random sample from the population of interest;
(ii) response to treatment observed for an individual in the trial, D i , reflects the potential response of an individual in the population assigned to that treatment, as discussed in
i ; (iii) treatment assignment or care of the patient in the trial does not depend on his marker value Y measured at enrollment. We discuss these conditions later in Section 8 but for now proceed with estimation methods assuming that they hold.
Suppose that we have independent observations (D
Observe that
, and G 2 (y) = Pr(Y ≤ y, T = 0). Thus, substituting the empirical estimators for the probabilities, a natural nonparametric estimator for θ(v) is
,
respectively. Basically, we determine the empirical quantileŷ v and calculate the proportion 9 of subjects on treatment A with Y >ŷ v who respond and the proportion on treatment B
with Y ≤ŷ v who respond. The weighted average is the empirical nonparametric estimator of θ(v).
Using the empirical process theory, we can show that
, where A(·) and
In Section 5 we calculate the large sample variance of θ np (v) in various settings using this expression. In applications, we can use the bootstrap method to calculate the standard error and confidence band for
detailed proof and arguments to justify bootstrapping are given in Appendix A.
Parametric Estimation
An alternative approach to estimating θ(v) is based on regression modeling. Suppose we use a model of the form
where R(v, T ) is a q-dimensional function of v and T . It is useful to write the model in terms of v, since θ(v) is considered a function of v for the reasons mentioned earlier. For example we might use the model
where R(v) is some function of v. We can write
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Therefore if estimates of α are available we can substitute them into the expression for θ(v)
One possibility is to use the maximum likelihood estimates of α based on the model (2), denoted by α. The corresponding estimator for θ(v) is denoted θ p (v). Note that this assumes that F is known in advance and can be used to calculate
More often the distribution function F will be estimated empirically from the n observations available. We write α for the estimator that solves the likelihood score equations but with
Now we consider the asymptotic properties of the estimators. We show in Appendix B that 
Asymptotic Relative Efficiencies
The three estimators θ np , θ p , and θ p require increasingly stronger assumptions to hold. θ p assumes that the regression model (2) holds and that F is known. Although θ p requires (2), it does not need F to be known since it uses the data to estimate F . Finally, θ np , the empirical estimator, is completely nonparametric. Using the asymptotic variance expressions we calculated the relative efficiencies of the estimators in settings where all three are consistent,
i.e., with (2) holding and F correctly specified for θ p . As expected, the estimators that assume more are more efficient asymptotically (Table 1) . The most important comparison between the estimators is between θ np and θ p since F will almost never be known in practice. Efficiency gains of 20-30% are achieved routinely with θ p relative to θ np in the scenarios we studied, although greater and lesser gains were also seen. Interestingly for the parametric estimator, knowledge of F further increases its efficiency, sometimes substantially. When R(v) = 10Φ −1 (v) for example, θ p is generally more than two times as efficient as θ p . This suggests that in practice parametric estimators of F may yield more efficient estimators of θ p (v) than that we employed, which are based on the empirical estimator of F .
Simulations
To assess the performance of the estimators in moderate sample sizes we conducted extensive simulation studies. We generated data for n = 200 subjects in a randomized trial with 
Application to CTS Data
The CTS study seeks to enroll 200 patients randomized to either median nerve decom- 
for some small τ > 0. We used is a more tenable task. Moreover, the bottom line of how to set the treatment assignment policy using a threshold criterion derives easily from the SI curve.
Discussion
We have proposed calculating the SI function, θ(v) = P[D = 1|(Y > y v , T = 1) or (Y < y v , T = 0)], to evaluate the impact of a treatment selection policy based on the criterion "Y > y v ." The curve shows the range of operating characteristics that can be achieved across different thresholds y v , where operating characteristics are defined in terms of the overall population response rate, i.e., θ(v), and the proportion of the population assigned to treatment B, i.e., v. We have mentioned that there are some similarities with receiver operative characteristic (ROC) curves used to evaluate diagnostic tests (Pepe 2000) , but the purpose and application is very different. A potentially important use of the curve is for comparing different markers in regards to their capacities for selecting treatments. We have not addressed formal methods for making comparisons in this paper but propose to develop methods for such purposes in the future. in terms of expectations:
and estimation methods analogous to those described in this paper, θ np (v) and θ p (v), could be pursued. Alternative definitions for θ(v) are also possible of course, using quantiles instead of expectations, for example. If the selection marker Y is discrete, the SI curve is a discrete function. Again procedures described here already can be used to estimate θ(v).
Comparisons between markers are less straightforward with discrete Y however than they are for continuous Y . In particular, decision criteria based on
may not yield comparable proportions of subjects assigned to treatment A, where subscripts here denote markers 1 and 2 respectively.
We have noted that there are several important assumptions that must be made about the clinical trial for valid estimation of the population response rate θ(v) from it. These are listed as items (i), (ii) and (iii) in Section 3. Item (i) is violated if subjects enrolling in the trial are not a simple random sample from the population. Although eligibility criteria attempt to define the population, this may not succeed, particularly if subjects self select to the study. This limits the generalizability of trial results to the "eligible" population and therefore applies to our problem of estimating the population SI curve too. If characteristics of the trial population simply differs from the population of interest in the distribution of some known covariates, one could reweight the data according to the population distribution and proceed with estimation. In the CTS study, one of the 3 study clinics is the Seattle Veterans Affairs Medical Center. Therefore, males will likely be over represented in the study. A reweighting scheme could be employed to adjust for this. The condition item (ii)
relates to the response of patients observed in the trial being reflective of their response to treatment offered in the population setting. If patient care or compliance in the trial differs from what occurs in the population then this condition will not be met. Again, this is a general issue regarding the interpretation of trial results for populations and highlights the need to conduct trials in ways that reflect general practice. The final requirement, item (iii), is that in the trial, Y is not used to select treatment or to dictate any aspect of patient care. This is ensured in the CTS study by having the MRNI performed by personnel not involved in patient care and storing the images until after the patient has completed the 12 month study.
Although the SI curve is one perspective from which to evaluate treatment selection markers, selection markers could be evaluated using other summary statistical measures too. For example, a utility function that incorporates notions of cost and benefit might be employed. A referee suggests the criterion to assign treatment A if the probability of benefit on A given Y > y exceeds that on B by a critical amount δ, i.e., if d + (v) > δ. We hope that this paper will at a minimum stimulate statisticians to think critically and in new ways about the general problem of how to evaluate treatment selection markers. Van der Varrt (2000) . Asymptotic Statistics. Cambridge: Cambridge University Press. Van der Varrt, A.W. and Wellner, J.A. (2000) . Weak Convergence and Empirical Processes.
New York: Springer-Verlag.
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Appendix A Large sample properties of θ np (v)
Asymptotic distribution theory for θ np (v) follows from that of the component empirical pro-
where
With some straightforward algebra, letting ∆G(y, x) = G(y) − G(x), we can show
θ is Hadamand-differentiable and the derivative can be derived by the chain rule (van der
Vaart and Wellner 2000, §3.9). Let f (y) =
for some positive , using the functional delta method, √ n{ θ np (v) − θ(v)} converges to a Gaussian process Z where,
In applications, we can use the bootstrap method to calculate a confidence band for θ(v)
for v ∈ [a, b] (0 < a < b < 1). This follows from theory for the bootstrap given in van der
Vaart and Wellner (2000, §3.9.3).
. . , Z n ) be the observed data set and Θ B = (Z 1 (B), Z 2 (B), . . . , Z n (B)) be the B th resampling bootstrap dataset, Theorem 2. √ n{ θ p (v) − θ(v)} converges to a Gaussian process Z p with covariance structure
Now we consider θ p (v). First, we derive the large sample properties ofα. For technical reasons we restrict estimation ofα to F * n (Y i ) ∈ (a, b), a proper subset of (0,1), and assume that R(v, t) has uniformly continuous and bounded partial derivatives R (1) (v, t) in the interval (a− 0 , b+ 0 ), 0 < a < b < 1, for some positive 0 . If this fails at some interior points, we can restrict estimation to the union S s=1 (a s , b s ) where the condition does hold. Let
The estimatorα is the solution to the following estimating equations
Consistency ofα
First we show √ n{F * n − F } converges to a tight Gaussian process. Note
Gaussian process, and
since |F n (y) ≤ 1|. Hence the result follows.
Denote the true value of α by α 0 . The estimatorα maximizes the concave function of α
By the Median Value Theorem,
whereR i is on the line segment between R(Ŵ i , T i ) and R(W i , T i ). Since sup y∈R |F * n (y) − F n (y)| < → 0, for any > 0, there exists N such that sup y∈R |F *
Replacing the right side of (B.1) by its upper bound, we have, for n > N 0 ,
The last equality follows from that √ n[R{F R{F, t}] converges to 0 in distribution by Slutsky theorem for t = 0, 1. Coupled with
. By Corollary II.2 of Andersen and Gill (1982) , the consistency ofα follows.
Asymptotic normality ofα
By a Taylor series expansion,
and I q is a q × q identity matrix, and Q(α 0 ; Z i ,Ẑ i ) is a q dimensional vector with the m th element equal to
E is a q × q matrix with the m th column equal to α and all other columns equal to 0. Now |λ jlm (α 0 ; z)| < M for j = 1, 2, where "<" holds elementwisely. Hence
The last equality follows from that √ n [R{F * n , t} − R{F, t}] converges to a Gaussian process on (a − 0 , b + 0 ) by the delta method and hence [R{F * n , t} − R{F, t}] converges in probability to 0 and then use the Slutsky theorem. Hence (B.3) = o p (1). Next, by adding and subtracting a term, (B.2) can be expressed as
(B.5)
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The last equality follows from that the process
converges to 0 on (a − 0 , b + 0 ) by the delta method. Now we show (B.4) is equal to
By DKW inequality (van der Vaart, 2000, P268),
Combining (B.7-B.10)), for n > max(N ),
and (B.6) holds. Therefore
(B.11)
is a V-statistic with mean 0. It is easy to show ξ has finite variance. Hence √ nξ has the same asymptotic distribution as √ nξ * (Serfling, 1967, §5.7.3) , where
is the corresponding U-statistic. And √ nξ * is equivalent to (van der Vaart, 2000, §12.1)
where 12) and z = (d, y, t) T , with the last two equalities in (B.12) follow from conditional expectation arguments. Hence
By the central limit theorem, √ nŨ (α 0 ;Ŷ ) is asymptotically normal with mean 0 and variance
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The last equation follows from
Now by another Taylor series expansion,
where α * is on the line segment between α and α 0 , and
. Using similar arguments as those for proving l(α;
a Taylor series expansion, and Γ (α 0 ; Z) − Γ(α 0 ) = o p (1) by law of large number. In light of the consistency ofα and hence α * ,Γ(α * , Z) converges to Γ(α 0 ) in probability. Therefore, √ n(α − α 0 ) is asymptotically normal with variancẽ
which is equal to
The large sample properties of θ p then follow by an application of the functional delta method.
Theorem 3. √ n{ θ p (v) − θ(v)} converges to a Gaussian process Z p with covariance structure
And the following theorem follows fromṼ α > pd V α . Table 2 Results of simulation studies. ASD, standard deviation calculated using asymptotic theory; SD, empirical standard deviation across simulated data sets ; SE, average of estimated standard errors; CP, coverage probability of the 95% Wald confidence interval. 
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